EGFR and non-small cell lung carcinoma: Similarly, a gatekeeper mutation in the kinase domain of EGFR (T790M) was found in 50−60% of NSCLC patients resistant to the first‐ and second‐generation EGFR‐TKIs.55, 56, 57